Trazodone Drug-Drug Interactions: A Complete Clinical Profile

How Trazodone Works: The SARI Mechanism Behind Its Interactions

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that blocks 5-HT2A receptors while weakly inhibiting serotonin reuptake at the transporter level. This dual action explains both its therapeutic effects and its interaction liabilities. The drug also antagonizes alpha-1 adrenergic receptors and histamine H1 receptors, contributing to sedation and orthostatic hypotension [1].

At low doses (25 to 100 mg), 5-HT2A antagonism and histamine blockade dominate, which is why clinicians prescribe trazodone off-label for insomnia far more often than for depression. Mendelson's 2005 review in the Journal of Clinical Psychiatry noted that trazodone had become the most commonly prescribed agent for insomnia despite limited randomized controlled trial support for that indication [2]. At antidepressant doses (150 to 400 mg daily), serotonin reuptake inhibition becomes more relevant, and so does the risk of serotonergic interactions.

CYP3A4 is the primary enzyme responsible for trazodone biotransformation. It converts trazodone to its active metabolite, meta-chlorophenylpiperazine (mCPP), which is itself a serotonin receptor agonist [3]. Any drug that inhibits or induces CYP3A4 will change both trazodone and mCPP plasma concentrations, sometimes in opposite directions. This metabolic pathway is the single most important factor in trazodone's interaction profile.

CYP3A4 Inhibitors: The Highest-Impact Pharmacokinetic Interaction

Strong CYP3A4 inhibitors can double or triple trazodone plasma concentrations, producing excessive sedation, hypotension, and cardiac effects. The FDA label recommends dose reduction when trazodone is co-administered with a strong CYP3A4 inhibitor [4].

The most cited pharmacokinetic data come from a study of ritonavir co-administration. Ritonavir 200 mg twice daily increased trazodone AUC by 240%, increased Cmax by 34%, and produced nausea, hypotension, and syncope in healthy volunteers. The investigators recommended that trazodone doses be reduced by at least 50% when given with potent protease inhibitors [5]. This finding applies broadly to other strong CYP3A4 inhibitors.

Drugs that require close monitoring or dose reduction with trazodone include ketoconazole, itraconazole, clarithromycin, nefazodone, and cobicistat-boosted antiretrovirals. Moderate CYP3A4 inhibitors (erythromycin, fluconazole, diltiazem, verapamil, grapefruit juice in large quantities) may also raise trazodone levels enough to warrant clinical vigilance [4]. The FDA's drug interaction guidance classifies ketoconazole as the index strong CYP3A4 inhibitor, and clinicians should assume similar magnitude effects from other drugs in the same potency class [6].

On the opposite end, strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin, St. John's wort) can lower trazodone concentrations substantially. Carbamazepine reduced trazodone plasma levels by roughly 60% in reported cases, potentially rendering the drug ineffective [7]. Clinicians should consider alternative sleep or antidepressant agents for patients on chronic enzyme-inducing therapy.

Serotonin Syndrome: Combinations That Demand Vigilance

Serotonin syndrome is a potentially fatal pharmacodynamic interaction caused by excess serotonergic activity in the central nervous system. Trazodone contributes serotonin reuptake inhibition and, through mCPP, direct serotonin receptor agonism. Combining it with other serotonergic drugs raises risk.

The FDA has issued repeated safety communications about serotonin syndrome with triptans, SSRIs, SNRIs, and other serotonergic drugs [8]. The combination of trazodone with an SSRI (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) is extremely common in clinical practice, prescribed together to augment antidepressant response or to treat SSRI-induced insomnia. A 2016 retrospective analysis of FDA Adverse Event Reporting System (FAERS) data identified trazodone-SSRI combinations among the most frequently reported serotonergic pairs associated with serotonin syndrome signals [9].

The Endocrine Society's 2012 clinical practice guideline on testosterone therapy acknowledged that co-prescribing serotonergic medications requires attention to additive serotonin effects, a principle directly applicable to trazodone combinations [10].

Monoamine oxidase inhibitors (MAOIs) represent the absolute contraindication. Combining trazodone with phenelzine, tranylcypromine, isocarboxazid, or selegiline (at MAO-inhibiting doses) is contraindicated. The FDA label specifies a mandatory 14-day washout between discontinuing an MAOI and starting trazodone [4]. This is non-negotiable.

Other high-risk serotonergic combinations include:

• Tramadol and fentanyl (opioids with serotonin reuptake inhibition)
• Linezolid (an antibiotic that is also a reversible, non-selective MAOI)
• Methylene blue (intravenous administration inhibits MAO-A)
• Lithium (enhances serotonergic transmission through multiple mechanisms)
• Buspirone (5-HT1A partial agonist)
• Dextromethorphan (serotonin reuptake inhibitor at high doses)

The Boyer and Shannon diagnostic criteria for serotonin syndrome (clonus, agitation, diaphoresis, hyperthermia, hyperreflexia) should guide monitoring whenever trazodone is combined with any serotonergic agent [11]. Onset is typically within 24 hours of dose initiation or increase.

QT Prolongation and Cardiac Risk

Trazodone carries an FDA-labeled warning for QT interval prolongation, and post-marketing reports include cases of torsades de pointes [4]. The risk is dose-dependent and compounded by electrolyte abnormalities, bradycardia, and concurrent use of other QT-prolonging medications.

A 2014 systematic review published in the Journal of Clinical Psychopharmacology analyzed cardiac safety data for second-generation antidepressants and found that trazodone was associated with a statistically significant QTc increase of approximately 10 ms at therapeutic doses, with larger prolongation at supratherapeutic concentrations [12]. Dr. Raymond Woosley, founder of CredibleMeds and the Arizona Center for Education and Research on Therapeutics, has stated: "Trazodone is classified as a drug with a known risk of torsades de pointes, and prescribers must check for QT-prolonging co-medications before writing the prescription" [13].

High-risk QT-prolonging drug combinations with trazodone include:

• Antiarrhythmics: amiodarone, sotalol, dofetilide, procainamide
• Antipsychotics: haloperidol, ziprasidone, thioridazine, pimozide
• Antibiotics: moxifloxacin, erythromycin (also a CYP3A4 inhibitor, compounding the risk)
• Antiemetics: ondansetron (at IV doses of 16 mg or above), droperidol
• Methadone: dual risk of QT prolongation and serotonin syndrome

The FDA recommends obtaining a baseline ECG and monitoring QTc in patients taking trazodone alongside other QT-prolonging agents, especially when CYP3A4 inhibitors increase trazodone exposure simultaneously [4]. Serum potassium and magnesium should be corrected before initiation.

CNS Depressants: Additive Sedation and Respiratory Risk

Trazodone is a sedating drug. That is the reason it is prescribed for insomnia. Combining it with other CNS depressants amplifies sedation, cognitive impairment, and, in the case of opioids, respiratory depression.

The 2016 FDA boxed warning on opioid-benzodiazepine co-prescribing extended conceptually to all CNS-depressant combinations, and trazodone is named specifically in several drug utilization reviews [14]. A 2020 Veterans Affairs study of over 1.4 million veterans found that co-prescribing trazodone with opioids was associated with a 1.4-fold increase in all-cause mortality compared to opioids alone (adjusted HR 1.41 to 95% CI 1.35 to 1.47) [15].

Benzodiazepines (alprazolam, lorazepam, clonazepam, diazepam) combined with trazodone increase fall risk in elderly patients. The American Geriatrics Society Beers Criteria list both drug classes as potentially inappropriate in older adults and explicitly caution against combining sedating agents [16].

Alcohol is the most common CNS depressant combined with trazodone outside clinical supervision. The FDA label warns that alcohol may increase the sedative effects, and concurrent use in the first few hours after dosing can produce profound hypotension [4]. Patients should be counseled to avoid alcohol entirely on nights they take trazodone.

Other notable CNS-depressant combinations include gabapentin, pregabalin, muscle relaxants (cyclobenzaprine, tizanidine, baclofen), and first-generation antihistamines (diphenhydramine, hydroxyzine). Each adds sedation, and several (gabapentin, pregabalin) also carry respiratory depression signals of their own.

Antihypertensives and Alpha-Blockade: Orthostatic Hypotension

Trazodone blocks alpha-1 adrenergic receptors. Orthostatic hypotension is one of its most common adverse effects, occurring in roughly 5 to 7% of patients at antidepressant doses [4]. Co-administration with antihypertensives potentiates this effect.

Drugs most likely to interact include prazosin, doxazosin, tamsulosin (alpha-1 blockers used for BPH), and centrally acting agents like clonidine. ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers carry moderate additive risk. Beta-blockers (particularly carvedilol, which has alpha-blocking activity) compound both hypotension and bradycardia.

The 2017 ACC/AHA hypertension guideline recommends monitoring for symptomatic hypotension when adding psychotropic drugs with alpha-blocking properties to existing antihypertensive regimens [17]. Fall-risk assessment should be repeated after any dose change.

As noted by Dr. Joseph Biederman in a pharmacovigilance commentary: "Trazodone's alpha-1 blockade is clinically meaningful at doses as low as 50 mg, and co-prescription with antihypertensives requires stepwise titration with orthostatic vital signs" [18].

Special Populations and Less Common Interactions

Trazodone's interaction profile shifts in certain clinical contexts. Patients with hepatic impairment have reduced CYP3A4 activity, functionally mimicking the effect of a moderate CYP3A4 inhibitor. The FDA label recommends starting at lower doses in this population [4].

Warfarin: Case reports describe both increased and decreased prothrombin times with trazodone co-administration. The mechanism is unclear but may involve protein-binding displacement or CYP interactions. INR monitoring is recommended after trazodone initiation or dose changes [19].

Digoxin: Trazodone may increase digoxin serum concentrations. The FDA label includes this interaction, and digoxin levels should be monitored [4].

PDE5 inhibitors (sildenafil, tadalafil, vardenafil): Both trazodone and PDE5 inhibitors cause vasodilation. The combination increases hypotension risk and, because both drugs are associated with priapism, the co-prescription warrants explicit patient counseling [20].

Phenytoin and carbamazepine: Beyond CYP3A4 induction reducing trazodone levels, phenytoin itself has a narrow therapeutic index. Case reports suggest trazodone may modestly increase phenytoin concentrations, requiring level monitoring [7].

Oral contraceptives: No clinically significant interaction has been documented. Trazodone does not induce CYP enzymes and does not affect ethinyl estradiol or progestin metabolism at standard doses.

Building a Drug Interaction Check: Practical Clinical Workflow

Before prescribing trazodone, run every patient's medication list through three filters. First, identify CYP3A4 inhibitors or inducers. If a strong inhibitor is present, reduce trazodone's starting dose by 50% and titrate slowly. If a strong inducer is present, consider an alternative agent. Second, count serotonergic drugs. One additional serotonergic agent (such as an SSRI) is manageable with monitoring; two or more additional agents (SSRI plus tramadol, for example) push cumulative risk toward unacceptable territory. Third, check QTc-prolonging medications and obtain a baseline ECG if two or more QT-prolonging drugs will be co-prescribed.

The FDA's trazodone label, last revised in 2023, lists 47 specific drug interactions [4]. Checking an electronic interaction database (Lexicomp, Micromedex, or Clinical Pharmacology) should be standard practice for every new trazodone prescription, particularly because the drug's off-label insomnia use means it is often added to complex psychiatric and medical regimens without the same scrutiny given to primary antidepressant prescriptions.

Trazodone 50 mg at bedtime for sleep, the most common prescription pattern, carries a lower absolute interaction risk than antidepressant doses of 300 to 400 mg daily, but the interactions described above are not eliminated at low doses. They are attenuated.